The Medicines and Healthcare products Regulatory Agency (MHRA) has published Drug Safety Update for December 2012 (PDF).
This update contains drug safety advice informing clinicians of an increased risk of serious skin reactions in patients of European descent or Japanese origin with the HLA-A*3101 allele when carbamazepine, oxcarbazepine and eslicarbazepine is used. The current data do not support pre-treatment screening but any individuals known to have this allele should only be started on these treatments after careful consideration of the benefits and risks.
This issue also contains the annual drug safety quiz that tests drug safety knowledge based on the updates published this year. Completion of the quiz may be a useful way to demonstrate continuing professional development.
Action: Clinicians will find this publication to be a useful review of current issues in drug safety.